S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
66,000% upside on tiny biotech? (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
66,000% upside on tiny biotech? (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
66,000% upside on tiny biotech? (Ad)
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
66,000% upside on tiny biotech? (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
66,000% upside on tiny biotech? (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
66,000% upside on tiny biotech? (Ad)
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
66,000% upside on tiny biotech? (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
66,000% upside on tiny biotech? (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
66,000% upside on tiny biotech? (Ad)
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
66,000% upside on tiny biotech? (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
66,000% upside on tiny biotech? (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
66,000% upside on tiny biotech? (Ad)
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
NASDAQ:CTXR

Citius Pharmaceuticals (CTXR) Stock Price, News & Analysis

$0.76
-0.03 (-3.80%)
(As of 02/23/2024 ET)
Today's Range
$0.76
$0.79
50-Day Range
$0.60
$0.84
52-Week Range
$0.60
$1.71
Volume
418,988 shs
Average Volume
698,607 shs
Market Capitalization
$120.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Citius Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
426.3% Upside
$4.00 Price Target
Short Interest
Bearish
7.30% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
210.53%
From $0.19 to $0.59 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.04 out of 5 stars

Medical Sector

379th out of 941 stocks

Pharmaceutical Preparations Industry

168th out of 430 stocks


CTXR stock logo

About Citius Pharmaceuticals Stock (NASDAQ:CTXR)

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

CTXR Stock Price History

CTXR Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
AI Stock Caught Trading Under Secret Name
We have uncovered perhaps the most unusual AI stock we've ever seen.It's expected to see massive revenue this year - $215 billion.  The company holds over 29,000 patents in the U.S. It pays an enormous dividend.
Citius Ekes out Gains as Trials End
Citius Pharmaceuticals Inc CTXR
See More Headlines
Receive CTXR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Citius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
12/29/2023
Today
2/25/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CTXR
Fax
N/A
Employees
22
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$4.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+426.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-32,540,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.54 per share

Miscellaneous

Free Float
135,231,000
Market Cap
$120.92 million
Optionable
Optionable
Beta
1.43

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Leonard L. Mazur (Age 79)
    Co-Founder, CEO, Chairman & Secretary
    Comp: $676.88k
  • Mr. Myron Z. Holubiak (Age 77)
    Co-Founder & Executive Vice Chairman
    Comp: $641.25k
  • Mr. Gary F. Talarico (Age 69)
    Executive Vice President of Operations
  • Ms. Ilanit Allen
    Vice President of Investor Relations & Corporate Communications
  • Dr. Alan Lader Ph.D.
    Senior VP and Head of Clinical Operations & Quality Assurance
  • Mr. Dhananjay G. Wadekar (Age 70)
    Senior Vice President of Business Strategy
  • Mr. Kelly Creighton Ph.D.
    Executive Vice President of Chemistry, Manufacturing & Controls
  • Mr. Nikolas Burlew
    Executive Vice President of Quality Assurance
  • Ms. Catherine Kessler M.S.
    Executive Vice President of Regulatory Affairs














CTXR Stock Analysis - Frequently Asked Questions

Should I buy or sell Citius Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Citius Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CTXR shares.
View CTXR analyst ratings
or view top-rated stocks.

What is Citius Pharmaceuticals' stock price target for 2024?

1 brokers have issued twelve-month target prices for Citius Pharmaceuticals' stock. Their CTXR share price targets range from $4.00 to $4.00. On average, they expect the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 426.3% from the stock's current price.
View analysts price targets for CTXR
or view top-rated stocks among Wall Street analysts.

How have CTXR shares performed in 2024?

Citius Pharmaceuticals' stock was trading at $0.7565 on January 1st, 2024. Since then, CTXR shares have increased by 0.5% and is now trading at $0.76.
View the best growth stocks for 2024 here
.

Are investors shorting Citius Pharmaceuticals?

Citius Pharmaceuticals saw a drop in short interest in the month of January. As of January 31st, there was short interest totaling 11,610,000 shares, a drop of 16.7% from the January 15th total of 13,940,000 shares. Based on an average daily volume of 574,500 shares, the days-to-cover ratio is presently 20.2 days.
View Citius Pharmaceuticals' Short Interest
.

When is Citius Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our CTXR earnings forecast
.

How were Citius Pharmaceuticals' earnings last quarter?

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) issued its earnings results on Friday, December, 29th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by $0.05.

When did Citius Pharmaceuticals' stock split?

Shares of Citius Pharmaceuticals reverse split before market open on Friday, June 9th 2017. The 1-15 reverse split was announced on Thursday, June 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 8th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Citius Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Citius Pharmaceuticals investors own include Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Novan (NOVN), ADMA Biologics (ADMA), SCYNEXIS (SCYX), Aeterna Zentaris (AEZS), CBL & Associates Properties (CBL), KushCo (KSHB) and Gran Tierra Energy (GTE).

Who are Citius Pharmaceuticals' major shareholders?

Citius Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.34%), Barclays PLC (0.11%), Goldman Sachs Group Inc. (0.06%), Kestra Advisory Services LLC (0.05%), Simplex Trading LLC (0.00%) and Citadel Advisors LLC (0.00%).
View institutional ownership trends
.

How do I buy shares of Citius Pharmaceuticals?

Shares of CTXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CTXR) was last updated on 2/25/2024 by MarketBeat.com Staff